← All trials
NCT03694405
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2018
- Primary completion
- Dec 31, 2019
- Completion date
- Mar 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 324
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Canadian Immunization Research NetworkLead sponsor
- Dalhousie UniversityCollaborator
- University of British ColumbiaCollaborator
- University of British ColumbiaOverall official - principal investigator
- University of CalgaryCollaborator
- University of CalgaryCollaborator
- Canadian Center for VaccinologyCollaborator
- Provincial Health Services AuthorityCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.